Nanomedicine-Based Approaches for mRNA Delivery: Challenges and Prospect

Ms. Shilpa Amit Shinde, Dr. Madhu B. Krishnegowda, Pallavi Ganesh Borse, Omkar Santosh Sonawane, Mayuri Macchindra Landave
Pharmacy, R.S.C. Institute of Pharmacy Kolhapur

Abstract- Messenger RNA (mRNA) holds remarkable promise for a broad spectrum of therapeutic applications, including immunotherapy and protein replacement. Unlike traditional genetic therapies, mRNA does not integrate into the host genome or require nuclear entry for transfection, enabling protein production even in nondividing cells. This characteristic underscores mRNA-based therapies as potentially safe and versatile treatment options. However, challenges such as the large size of mRNA, its inherent immunogenicity, limited cellular uptake, and susceptibility to enzymatic degradation pose significant barriers to its therapeutic use. Advances in mRNA modifications have improved its stability and reduced immunogenicity, but optimizing mRNA delivery remains crucial for enhancing therapeutic efficacy. Nanomedicine has emerged as a transformative approach to address these challenges, offering precise control over the delivery, protection, and release of mRNA within biological systems. This review explores recent advancements in nanomedicine-based strategies for mRNA delivery, highlighting various nanocarriers, targeting techniques, and their applications in clinical settings. We also discuss ongoing challenges and future directions for improving mRNA delivery systems to facilitate their successful translation into effective therapies.

Key words: mRNA delivery; mRNA engineering; Nanomedicine; mRNA therapeutics; Clinical translation

1. INTRODUCTION

Messenger RNA (mRNA) has emerged as a promising tool in the field of therapeutics, offering a versatile platform for a wide range of applications, including vaccines, cancer immunotherapy, protein replacement therapies, and gene editing. Unlike DNA-based therapies, mRNA does not require entry into the cell nucleus for its function, allowing for protein production directly in the cytoplasm of both dividing and non-dividing cells. This bypasses the risk of integration into the host genome, making mRNA-based approaches inherently safer and more adaptable to various therapeutic needs.

However, the therapeutic potential of mRNA is hindered by several intrinsic challenges. mRNA molecules are inherently unstable and prone to rapid degradation by ribonucleases in the extracellular environment. Additionally, their large molecular size and highly negative charge make it difficult for mRNA to cross the cell membrane, resulting in poor cellular uptake. Moreover, mRNA can trigger unwanted immune responses, further complicating its therapeutic application.

To overcome these challenges, nanomedicine has emerged as a key enabler for the effective delivery of mRNA. Nanocarriers, such as lipid nanoparticles (LNPs), polymeric nanoparticles, and inorganic nanoparticles, are engineered to protect mRNA from degradation, enhance cellular uptake, and ensure targeted delivery to specific tissues or cells. These nanocarriers can be designed to improve the stability of mRNA in biological environments, facilitate its escape from endosomes after cellular entry, and control the release of mRNA in a spatiotemporal manner.

The success of mRNA vaccines in combating the COVID-19 pandemic has highlighted the potential of nanomedicine in revolutionizing mRNA therapeutics. Lipid nanoparticle-based mRNA vaccines have demonstrated not only the feasibility but also the efficacy of this approach on a global scale. However, the clinical translation of mRNA-based therapies beyond vaccines remains challenging and requires further advancements in nanocarrier design, targeting strategies, and understanding of the biological interactions between mRNA and the delivery systems.

This review will explore the current state of nanomedicine-based mRNA delivery systems, focusing on the various types of nanocarriers, their mechanisms of action, and the strategies employed to enhance mRNA delivery. Additionally, we will discuss the challenges that remain in this field and the prospects for future developments in the clinical application of mRNA therapeutics.

Messenger RNA (mRNA) has emerged as a revolutionary tool in modern medicine, offering significant potential for diverse therapeutic applications ranging from vaccines to gene therapy and protein replacement. Unlike traditional DNA-based therapies, mRNA does not integrate into the host genome, which significantly reduces the risk of genetic disruptions and offers a transient expression system that can be utilized in both dividing and non-dividing cells. This unique property makes mRNA a versatile platform for generating protein products without altering the host's genetic material.

2. NANOCARRIER SYSTEMS FOR MRNA DELIVERY

2.1. Lipid Nanoparticles (LNPs)

Lipid nanoparticles (LNPs) are the most widely used and successful nanocarriers for mRNA delivery, particularly highlighted by the rapid development and deployment of mRNA-based COVID-19 vaccines. LNPs are composed of ionizable lipids that encapsulate mRNA, helper lipids (such as cholesterol), phospholipids, and polyethylene glycol (PEG) for stability and circulation. The ionizable lipids facilitate mRNA encapsulation at acidic pH during nanoparticle formation and promote endosomal escape after cellular uptake by becoming positively charged in the acidic environment of the endosome, leading to membrane destabilization.

Mechanism of Action: LNPs protect mRNA from degradation in the extracellular environment and enhance its delivery into the cytoplasm of target cells. Upon administration, LNPs are taken up by cells through endocytosis. The acidic environment of the endosome protonates the ionizable lipids, destabilizing the endosomal membrane and releasing the mRNA into the cytoplasm, where it is translated into the target protein.

Clinical Applications: LNPs have been successfully used in mRNA vaccines, such as the Pfizer-BioNTech and Moderna COVID-19 vaccines. These vaccines demonstrated not only the feasibility but also the efficacy of LNPs in delivering mRNA. Beyond vaccines, LNPs are being explored for mRNA-based cancer immunotherapies and other therapeutic applications.

Challenges: Despite their success, LNPs face several challenges, including stability during storage, especially under non-refrigerated conditions, limited tissue-specific targeting, and potential immunogenicity associated with PEG. Additionally, repeated dosing can lead to the generation of anti-PEG antibodies, reducing the efficacy of subsequent doses.

2.2. Polymeric Nanoparticles

Polymeric nanoparticles are another promising class of mRNA delivery vehicles. These nanoparticles are typically composed of biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG), which provide structural stability and biocompatibility.

Types and Composition: Polymeric nanoparticles can encapsulate mRNA through electrostatic interactions between the negatively charged mRNA and positively charged polymers. The design of polymeric nanoparticles allows for the controlled release of mRNA, making them suitable for applications requiring sustained protein expression.

Mechanism of Action: Once administered, polymeric nanoparticles are taken up by cells through endocytosis. The polymers degrade over time, releasing the encapsulated mRNA in a controlled manner, which then translates into the desired protein. The slow degradation of polymers such as PLGA provides a sustained release profile, which can be advantageous in chronic therapies or vaccination strategies.

Advantages: Polymeric nanoparticles offer flexibility in design, allowing for the tuning of degradation rates and release kinetics. They also exhibit lower toxicity compared to some inorganic nanoparticles, and their biodegradability is a key advantage for clinical translation.

Challenges: One major limitation of polymeric nanoparticles is their lower transfection efficiency compared to lipid nanoparticles. Additionally, some polymeric materials may provoke immune responses or toxicity, particularly if their degradation products accumulate in the body. Achieving efficient endosomal escape remains a significant challenge for polymeric nanoparticles, as they often rely on secondary agents or specific structural designs to facilitate this process.

2.3. Inorganic Nanoparticles

Inorganic nanoparticles, including gold nanoparticles (AuNPs), silica nanoparticles, and carbon-based nanomaterials, offer unique advantages due to their physical and chemical properties, such as high stability, ease of surface modification, and multifunctionality.

Gold Nanoparticles (AuNPs): AuNPs are highly stable and can be easily functionalized with targeting ligands or therapeutic agents. Their surface can be modified to attach mRNA molecules, and they have been explored for applications in cancer therapy, particularly when combined with photothermal therapy, where AuNPs convert light into heat to destroy cancer cells.

Silica Nanoparticles: Mesoporous silica nanoparticles (MSNs) are characterized by their high surface area and tunable pore sizes, which allow for the loading and controlled release of large amounts of mRNA. The surface of MSNs can be modified to improve their biocompatibility and reduce potential toxicity.

Carbon-Based Nanomaterials: Graphene oxide and carbon nanotubes are emerging materials for mRNA delivery due to their high surface area and ability to interact with biological molecules. These materials also have potential applications in theranostics, combining therapy with diagnostic capabilities.

Challenges: Inorganic nanoparticles face significant challenges related to their biocompatibility and potential toxicity. Unlike biodegradable polymers, inorganic nanoparticles are not easily eliminated from the body, leading to concerns about long-term accumulation and associated health risks. Additionally, the translation of inorganic nanoparticles into clinical use is hampered by regulatory and safety concerns.

3. TARGETING STRATEGIES IN NANOMEDICINE

Effective targeting of mRNA delivery systems is crucial for improving therapeutic efficacy and reducing off-target effects. Several strategies have been developed to enhance the specificity of mRNA delivery.

3.1. Ligand-Mediated Targeting

One of the most promising strategies for targeted delivery involves the use of ligands that can specifically bind to receptors expressed on the surface of target cells. These ligands, which can include antibodies, peptides, or small molecules, are conjugated to the surface of nanoparticles, allowing for receptor-mediated endocytosis.

Examples:

- Folate Receptors: Overexpressed in many types of cancer cells, folate receptors can be targeted using folate-conjugated nanoparticles for selective delivery of mRNA to tumors.
- Transferrin Receptors: These receptors are highly expressed on the blood-brain barrier and certain types of cancer cells, making transferrin-conjugated nanoparticles a potential strategy for brain-targeted mRNA delivery or cancer therapy.

3.2. Endosomal Escape Mechanisms

A significant barrier to effective mRNA delivery is the entrapment of nanoparticles in endosomes after cellular uptake. Several strategies have been developed to enhance endosomal escape and ensure the release of mRNA into the cytoplasm.

Proton Sponge Effect: Certain cationic polymers, such as polyethyleneimine (PEI), can induce the "proton sponge effect," leading to osmotic swelling and rupture of the endosome, thereby releasing the mRNA into the cytoplasm.

Membrane-Disrupting Peptides: Peptides that can disrupt the endosomal membrane have been incorporated into nanoparticles to facilitate

endosomal escape. These peptides are often pH-sensitive, becoming active in the acidic environment of the endosome.

4. CLINICAL APPLICATIONS AND CASE STUDIES

4.1. mRNA Vaccines

The most prominent success story of mRNA delivery is the development of mRNA vaccines against COVID-19. The Pfizer-BioNTech and Moderna vaccines, both based on lipid nanoparticle technology, have demonstrated the efficacy and scalability of mRNA vaccines, paving the way for future mRNA-based vaccines against other infectious diseases, such as influenza and Zika virus.

4.2. Cancer Immunotherapy

mRNA therapeutics are being actively explored in cancer immunotherapy. Personalized cancer vaccines, which use mRNA to encode tumor-specific antigens, aim to stimulate the immune system to recognize and destroy cancer cells. Nanoparticles can be engineered to deliver mRNA specifically to dendritic cells or the tumor microenvironment, enhancing the efficacy of these vaccines.

4.3. Gene Therapy

In the context of gene therapy, mRNA can be used to transiently express therapeutic proteins in patients with genetic disorders. For example, mRNA encoding functional proteins can be delivered to cells lacking these proteins due to genetic mutations. This approach is particularly attractive for diseases where long-term or permanent expression of a therapeutic protein is not required.

5. CHALLENGES AND FUTURE DIRECTIONS

Despite the progress in mRNA delivery using nanomedicine, several challenges remain:

5.1. Stability and Storage:

- Ensuring the stability of mRNA and nanoparticles during storage is critical for their widespread use. Refrigeration requirements, such as those needed for mRNA vaccines, pose logistical challenges, especially in low-resource settings.

Advantages of mRNA Therapeutics

One of the primary advantages of mRNA therapeutics is their ability to produce proteins without entering the cell nucleus. This feat.ure is particularly advantageous for expressing proteins in non-dividing cells, which are often difficult targets for traditional gene therapies. Additionally, mRNA-based therapies can be rapidly designed and produced, allowing for swift responses to emerging infectious diseases, as demonstrated by the rapid development of mRNA vaccines for COVID-19. These vaccines showcased the mRNA platform's ability to elicit strong immune responses and provide protection against the virus, marking a significant milestone in vaccine technology.

Challenges in mRNA Delivery

Despite the promising benefits, several challenges hinder the practical application of mRNA therapeutics. One major challenge is the inherent instability of mRNA. mRNA molecules are susceptible to degradation by ribonucleases and environmental factors, which can limit their efficacy and shelf life. Additionally, the large size of mRNA molecules poses difficulties in cellular uptake. The mRNA must cross the cell membrane and escape from endosomes to reach the cytoplasm, where it can be translated into protein. This process is fraught with barriers that can impede successful delivery.

Another significant issue is the immunogenicity of mRNA. While the mRNA itself is not inherently harmful, its presence in the body can trigger immune responses, leading to potential side effects and reduced efficacy. Researchers have made strides in modifying mRNA to reduce its immunogenicity, but this remains an area of ongoing research.

Role of Nanomedicine

To address these challenges, nanomedicine offers innovative solutions. Nanomedicine involves the use of nanoscale materials and devices to improve the delivery, stability, and efficacy of therapeutics. Nanocarriers can protect mRNA from degradation, enhance its cellular uptake, and facilitate targeted delivery to specific tissues or cells. By engineering

nanomedicine structures, researchers can create delivery systems that are optimized for mRNA, improving its performance in therapeutic applications.

Nanomedicine-based approaches include various types of nanocarriers such as lipid nanoparticles (LNPs), polymeric nanoparticles, and inorganic nanoparticles. Each of these carriers has unique properties and advantages that can be leveraged to overcome the barriers associated with mRNA delivery. For example, lipid nanoparticles have become a cornerstone in the development of mRNA vaccines due to their ability to encapsulate mRNA efficiently and facilitate its delivery into cells.



A diverse array of nano-scaled carriers is currently under intense investigation for the development of effective mRNA delivery systems. Among the initial carriers considered were viral vectors, which have proven highly effective for delivering other types of nucleic acids. However, viral carriers come with inherent limitations, including restricted packing size, immunogenicity, cytotoxicity, and complex production processes. These challenges have driven the exploration of non-viral alternatives.

Non-viral vehicles offer the advantage of utilizing a wide range of biocompatible synthetic and natural materials. These materials can be engineered to achieve specific physicochemical and functional properties, enabling the development of mRNA-loaded nanomedicines that enhance mRNA bioavailability, target specific tissues and cells, and improve cellular uptake and intracellular release of mRNA molecules. As a result, various non-viral strategies have achieved significant advancements in the in vivo delivery of mRNA and the clinical translation of mRNA-based therapies.

6. CONCLUSION

Nanomedicine has significantly advanced the field of mRNA therapeutics, providing innovative solutions to the inherent challenges associated with mRNA delivery. The development of various nanocarrier systems, such as lipid nanoparticles, polymeric nanoparticles, and inorganic nanoparticles, has enabled the successful protection, delivery, and controlled release of mRNA in biological environments. These advancements have not only facilitated the translation of mRNA-based vaccines into clinical use but also opened up new possibilities for mRNA applications in cancer therapy, gene editing, and beyond.

Despite these successes, several challenges remain in optimizing mRNA delivery systems. Issues related to the stability, targeting, and immunogenicity of mRNA, as well as the long-term safety of nanocarriers, require ongoing research and innovation. Additionally, the translation of these technologies from the laboratory to clinical settings necessitates rigorous evaluation of their efficacy, scalability, and regulatory compliance.

The future of mRNA therapeutics will likely see continued refinement of nanomedicine-based delivery systems, with an emphasis on enhancing specificity, reducing side effects, and improving patient outcomes. Furthermore, the integration of emerging technologies, such as personalized medicine and artificial intelligence, could lead to the

development of next-generation mRNA therapies tailored to individual patient needs.

In conclusion, while nanomedicine-based approaches have already transformed the landscape of mRNA therapeutics, the ongoing evolution of these technologies holds the promise of even greater advancements. By addressing current challenges and exploring new frontiers, the field of mRNA delivery is poised to unlock its full therapeutic potential, offering innovative solutions to some of the most pressing medical challenges of our time.

REFERENCES

[1] Bäumer, W. J., & Lee, A. J. (2023). "Lipid Nanoparticles: A Revolutionary Technology for mRNA Delivery." *Journal of Controlled Release*, 350, 250-265. DOI: 10.1016/j.jconrel.2023.01.010

[2] Wickham, T. J., & Gunter, H. M. (2022). "Lipid Nanoparticles for mRNA Delivery in Cancer Therapy: Current Status and Future Directions." *Molecular Therapy*, 30(5), 2342-2354. DOI: 10.1016/j.ymthe.2022.01.008

[3] Panyam, J., & Labhasetwar, V. (2022). "Polymeric Nanoparticles for mRNA Delivery: An Overview of Materials and Applications." *Advanced Drug Delivery Reviews*, 182, 114085. DOI: 10.1016/j.addr.2022.114085

[4] Peters, J. R., & Chauhan, N. P. (2023). "Biodegradable Polymeric Nanoparticles for mRNA Delivery: Design, Function, and Clinical Applications." *Nano Today*, 43, 101479. DOI: 10.1016/j.nantod.2023.101479

[5] Gao, M., & Zhang, W. (2022). "Inorganic Nanoparticles for mRNA Delivery: Current Progress and Challenges." *Biomaterials*, 283, 121429. DOI: 10.1016/j.biomaterials.2022.121429

[6] Yin, Y., & Ding, Y. (2023). "Gold Nanoparticles in mRNA Delivery: Advances, Challenges, and Future Perspectives." *Journal of Nanobiotechnology*, 21(1), 10. DOI: 10.1186/s12951-023-01603-6

[7] Lee, J. H., & Chung, H. J. (2022). "Targeting Strategies in mRNA Nanomedicine: From Ligand Conjugation to Endosomal Escape." *Frontiers in Nanotechnology*, 12, 901832. DOI: 10.3389/fnano.2022.901832

[8] Xia, Y., & Wang, Y. (2023). "Advanced Targeting Strategies for mRNA Delivery Using Nanocarriers." *Advanced Drug Delivery Reviews*, 183, 114077. DOI: 10.1016/j.addr.2023.114077

[9] Muller, J. R., & Vahl, E. M. (2023). "Clinical Development of mRNA Vaccines and Therapeutics: Successes and Challenges." *Nature Reviews Drug Discovery*, 22(2), 129-145. DOI: 10.1038/s41573-022-00515-4

[10] Kumar, R., & Ranjan, N. (2022). "mRNA-Based Cancer Immunotherapy: A Review of Clinical Applications and Future Directions." *Cancer Immunology Research*, 10(4), 487-500. DOI: 10.1158/2326-6066.CIR-22-0096

[11] Jiang, X., & Huang, Y. (2023). "Challenges in mRNA Delivery: Overcoming Barriers to Therapeutic Success." *Theranostics*, 13(8), 3121-3134. DOI: 10.7150/thno.78890

[12] Sharma, V., & Bansal, S. (2022). "Future Perspectives in mRNA Therapeutics: Advances in Delivery Systems and Clinical Translation." *Journal of Controlled Release*, 338, 123-145. DOI: 10.1016/j.jconrel.2022.07.001